Tim has led AgomAb Therapeutics as CEO since February 2019 and joined the board in March 2021. Since joining, he has raised a total of $240M and built a broad pipeline focused on growth factor biology and fibrotic indications. Agomab is an argenx spin-off, inheriting strong scientific pedigree from one of Belgium's most important biotech companies.
He holds an executive MBA from IMD Business School, where he was named Valedictorian, and two Master's degrees from Utrecht University. His career includes VP Corporate Development at AM-Pharma, where he led a $600M option-to-buy deal with Pfizer and executed a Phase IIb trial, as well as earlier work as a Senior Associate at Aescap Venture.